ArticleTranslational lung cancer research2025
Development and validation of a multivariable prognostic model incorporating black-blood magnetic resonance imaging-based meningeal lymphatic remodeling to predict therapy response in non-small cell lung cancer brain metastases.
Article in Translational lung cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Bidirectional roles of meningeal lymphatic vessels in brain metastases: friend and foe.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Brain metastases (BMs) from non-small cell lung cancer (NSCLC) remain a major clinical challenge, and existing prognostic tools such as the Graded Prognostic Assessment (GPA) do not incorporate imaging biomarkers or adequately reflect the impact of immunotherapy. Meningeal lymphatic vessels (mLVs), which regulate cerebrospinal fluid drainage and immune surveillance, have been implicated in tumor-immune interactions. We aimed to develop and internally validate a multivariable prognostic model integrating mLV remodeling measured by black-blood magnetic resonance imaging (BB-MRI) with clinical predictors to improve early prediction of treatment response. Methods: We retrospectively analyzed 130 patients with pathologically confirmed NSCLC (100 with BM, 30 without BM). Among the BM cohort, 56 patients achieved favorable treatment response [stable disease (SD) or partial response (PR)] and 44 experienced progressive disease (PD). Candidate predictors were pre-specified based on clinical relevance, and the final model incorporated total mLV diameter, immunotherapy exposure, sex, and extracranial lesion count. Internal validation was performed with 1,000 bootstrap resamples. Model performance was assessed by discrimination, calibration, and decision curve analysis (DCA). Results: The final multivariable model demonstrated good discrimination [area under the curve (AUC) =0.82; 95% confidence interval (CI): 0.75-0.90], excellent calibration, and consistent net clinical benefit across a range of threshold probabilities. The calibration and decision curves showed promising internal performance, but external validation is required before clinical application. Conclusions: BB-MRI-derived mLV remodeling may be an early and noninvasive indicator of treatment efficacy in BM. The proposed nomogram enables the individualized prediction of systemic therapy response, supporting precision immunotherapy for patients with intracranial metastases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.